Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial

被引：2
|
作者：
Ahn, Myung-Ju
Camidge, D. Ross
Tiseo, Marcello
Reckamp, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Langer, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William
Kerstein, David
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Univ Colorado Denver, Aurora, CO USA
[3] Univ Hosp Parma, Parma, Italy
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Odense Univ Hosp, Odense, Denmark
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[7] Univ Hosp Munich, Thorac Oncol Ctr Munich, Munich, Germany
[8] Swedish Canc Inst, Seattle, WA USA
[9] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[10] Otto Wagner Hosp, Vienna, Austria
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
[12] Yale Canc Ctr, New Haven, CT USA
[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
[14] Hosp Octubre, Dept Med Oncol, Madrid, Spain
[15] Vrije Univ VU Med Ctr, Amsterdam, Netherlands
[16] Levine Canc Inst, Charlotte, NC USA
[17] ARIAD Pharmaceut, Cambridge, MA USA
[18] Seoul Natl Univ Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20503
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
  • [32] Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC)
    Tan, Weiwei
    Wilner, Keith D.
    Lanzalone, Silvana
    Polli, Anna
    Zierhut, Matthew L.
    Nickens, Dana
    O'Byrne, Kenneth J.
    Blackhall, Fiona H.
    Shaw, Alice T.
    Salgia, Ravi
    Jaime, Jesus Correl
    Kim, Dong-Wan
    CANCER RESEARCH, 2015, 75
  • [33] Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)
    Kim, Young
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S378 - S379
  • [34] Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial
    Bazhenova, A.
    Gettinger, S. N.
    Langer, C. J.
    Salgia, R.
    Gold, K. A.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Haney, J.
    Rivera, V. M.
    Kerstein, D.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Brigatinib vs Crizotinib in patients (pts) with ALK inhibitornaive advanced ALK plus NSCLC from the phase 3 ALTA-1L trial
    Griesinger, F.
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Campelo, Garcia M. R.
    Kim, D. -W.
    Bearz, A.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 75 - 76
  • [36] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Montero, Alberto J.
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1211 - S1212
  • [37] Brigatinib (Alunbrig®) - New Option for Crizotinib-pretreated adult Patients with ALK-positive non-small cell Lung Carcinoma (ALK plus NSCLC)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (1-2) : 74 - 74
  • [38] Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naive anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Halawah, Hala
    Calamia, Matthias
    Gulick, Dexter
    Manasrah, AlMothana
    Alkhdour, Odai
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] INDIRECT TREATMENT COMPARISON OF ALECTINIB VS. BRIGATINIB IN ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Wong, W.
    Sheinson, D.
    VALUE IN HEALTH, 2019, 22 : S59 - S59
  • [40] Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Garcia Campelo, Maria Rosario
    Kim, Dong-Wan
    Griesinger, Frank
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Gupta, Neeraj
    Hanley, Michael J.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3592 - +
12345